+91 789 2456 581 | info@nckpharma.com
Tag

priority review

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused...
Read More

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.